Paul Paik

Paul Paik is a thoracic oncologist specializing in MET-driven NSCLC, with particular expertise in MET exon 14 skipping mutations and MET amplification as primary and secondary resistance mechanisms. He has participated in pivotal trials of tepotinib and capmatinib in MET exon 14-altered NSCLC and contributed to defining optimal diagnostic approaches for detecting this mutation class. His translational work characterizes mechanisms of acquired resistance to MET inhibitors and evaluates combination strategies. He is a respected educator in the field of precision thoracic oncology.